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Abstract

Key Points

IMPORTANCE In 2020, the Centers for Medicare & Medicaid Services revised its national coverage
determination, removing the requirement to obtain review from a Medicare-approved heart
transplant center to implant a durable left ventricular assist device (LVAD) for bridge-to-transplant
(BTT) intent at an LVAD-only center. The association between center-level transplant availability and
access to heart transplant, the gold-standard therapy for advanced heart failure (HF), is unknown.

Question Is the presence of a heart
transplant program associated with
differential evaluation for transplant or
transplant among patients who receive a
left ventricular assist device (LVAD)?
Findings In this cohort study of 22 221

OBJECTIVE To investigate the association of center transplant availability with LVAD implant

LVAD recipients from the Society of

strategies and subsequent heart transplant following LVAD implant before the Centers for Medicare

Thoracic Surgeons Intermacs database,

& Medicaid Services policy change.

patients receiving durable LVAD at
centers that also performed heart

DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study of the Society of Thoracic

transplants were significantly more

Surgeons Intermacs multicenter US registry database was conducted from April 1, 2012, to June 30,

likely to receive an LVAD as a bridge to

2020. The population included patients with HF receiving a primary durable LVAD.

transplant. In addition, patients treated
at a combined LVAD/transplant center
were more likely to receive a heart

EXPOSURES LVAD center transplant availability (LVAD/transplant vs LVAD only).

transplant in the subsequent 2 years.

MAIN OUTCOMES AND MEASURES The primary outcomes were implant strategy as BTT and
subsequent transplant by 2 years. Covariates that might affect listing strategy and outcomes were
included (eg, patient demographic characteristics, comorbidities) in multivariable models.

Meaning The findings of this study
suggest that the increased use of LVAD
at centers that do not perform

Parameters for BTT listing were estimated using logistic regression with center-level random effects
and for receipt of a transplant using a Cox proportional hazards regression model with death as a
competing event.

transplants has the potential to
contribute to inequities in access to
heart transplant, the gold-standard
therapy for advanced heart failure.

RESULTS The sample included 22 221 LVAD recipients with a median age of 59.0 (IQR, 50.0-67.0)
years, of whom 17 420 (78.4%) were male and 3156 (14.2%) received implants at LVAD-only centers.
Receiving an LVAD at an LVAD/transplant center was associated with a 79% increased adjusted odds
of BTT LVAD designation (odds ratio, 1.79; 95% CI, 1.35-2.38; P < .001). The 2-year transplant rate
following LVAD implant was 25.6% at LVAD/transplant centers and 11.9% at LVAD-only centers.

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

There was an associated 33% increased rate of transplant at LVAD/transplant centers compared with
LVAD-only centers (adjusted hazard ratio, 1.33; 95% CI, 1.17-1.51) with a similar hazard for death at 2
years (adjusted hazard ratio, 0.99; 95% CI, 0.90-1.08).
CONCLUSIONS AND RELEVANCE Receiving an LVAD at an LVAD-transplant center was associated
with increased odds of BTT intent at implant and subsequent transplant receipt for patients at 2
years. The findings of this study suggest that Centers for Medicare & Medicaid Services policy change
(continued)
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Abstract (continued)

may have the unintended consequence of further increasing inequities in access to transplant among
patients at LVAD-only centers.
JAMA Network Open. 2022;5(11):e2240646. doi:10.1001/jamanetworkopen.2022.40646

Introduction
Heart failure (HF) refractory to medical therapy affects approximately 300 000 people in the US and
is associated with up to a 75% 1-year mortality.1-6 Advanced therapies, including heart transplant and
durable left ventricular assist device (LVAD) implant, are life saving for patients with advanced HF,
with 1-year survival for both LVAD and transplant greater than 85%.7,8 In December 2020, the
Centers for Medicare & Medicaid Services (CMS) implemented a national coverage decision that
included relaxed restrictions at LVAD-only implanting centers.9 These changes included removing (1)
the therapeutic intent, (2) the requirement that the patient be active on the waiting list maintained
by the Organ Procurement and Transplantation Network when receiving a durable LVAD as a bridge
to transplant (BTT), and (3) the requirement that the implanting site, if different than the Medicareapproved transplant center, must receive written permission from the Medicare-approved transplant
center before implantation of a BTT LVAD.9
Although there is enthusiasm for the change, given the potential to make durable LVADs more
accessible, the association between the coverage change and access to heart transplant, the goldstandard therapy for advanced HF,10 is uncertain. On the one hand, it is plausible that removing the
requirement for determination of transplant ineligibility by a Medicare-approved heart transplant
center may facilitate access to durable LVAD therapy for appropriate patients while transplanteligible patients will continue to be referred to transplant centers for consideration for transplant. On
the other hand, by removing the coevaluation between Medicare-approved transplant programs and
nontransplant programs, there is a potential unintended consequence of transplant-eligible patients
not receiving a transplant.
This large-scale observational cohort study evaluated the association of transplant availability
at a center before the CMS policy change with its national coverage decision. Specifically, this study
examined the association between LVAD center transplant availability and therapeutic intent and
subsequent heart transplant following durable LVAD implant. It was hypothesized that there would
be a greater likelihood of durable LVAD implant as BTT and receipt of a heart transplant after durable
LVAD implant at Medicare-approved transplant centers compared with non–Medicare-approved
transplant centers (LVAD-only centers). This study’s findings may provide insight into the potential
association between the CMS policy change and equitable access to transplant for patients receiving
care at nontransplant centers.

Methods
Data Sources and Sample
The Society of Thoracic Surgeons (STS) Intermacs database was the primary data source (additional
details in eMethods 1 in Supplement 1). Center-level transplant status by year was determined by
publicly available data from the Organ Procurement and Transplantation Network.11 Hospital
characteristics were abstracted from the American Hospital Association Annual Survey from 2012.12
Transplant volume and center characteristics were linked to patient-level STS Intermacs data by the
data coordinating center at The University of Alabama at Birmingham. The deidentified analytical
data set was created through the STS Participant User File program. This study was approved as not
regulated owing to the use of deidentified data by the University of Michigan Institutional Review
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Board and followed the Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) reporting guideline.
The study population included all adults undergoing de novo primary durable continuous-flow
LVAD implantation between April 1, 2012, and June 30, 2020. The start date was based on the
availability of patient-level information in STS Intermacs, version 4.0. Patients were excluded if
undergoing LVAD exchange, had a concurrent right VAD, or were missing data on either age or
implantation center.

Outcomes
The prespecified primary outcomes were use of BTT therapeutic intention to treat and receipt of
heart transplant within 2 years following LVAD implant. The initial therapeutic intention-to-treat
strategy was categorized as BTT, bridge to candidacy for transplant, and destination therapy (full
details described in eMethods 2 in Supplement 1).13,14

Statistical Analysis
This study evaluated the association between Medicare-approved transplant center status for an
LVAD implant center for both initial BTT strategy and receipt of transplant at 2 years. The primary
independent variable of interest was center Medicare-approved heart transplant status (LVAD/
transplant or LVAD only), determined by whether a center performed any heart transplants during
the year in which an LVAD was placed. As such, centers that started or stopped performing
transplants would have patients in both groupings.
Continuous variables are displayed as median (IQR). Univariable comparisons were performed
using the Fisher exact test for categorical variables, Wilcoxon rank sum test for continuous variables
or zero-inflated Poisson regression. Trends in the number of LVAD/transplant and LVAD-only centers
and LVADs implanted by each center type were determined by linear regression.
Random-effects logistic regression was used to measure associations between center status
and BTT strategy intent at implantation accounting for unobserved center-level effects. Results are
presented as odds ratios and estimated marginal effects (ie, the percentage of estimated BTT use by
center type). Candidate variables that could be associated with both the eligibility for and receipt of
transplant (patient demographic characteristics, clinical characteristics [eg, comorbidities], and
hospital data [eg, bed size]) were selected by HF experts for model inclusion (eTable 1 in
Supplement 1). Race was reported by sites and categorized as American Indian or Alaska Native,
Asian, African American or Black, Hawaiian or other Pacific Islander, White, Unknown/Undisclosed,
or Other/none of the above. Due to low numbers in groups, race was categorized as White, Black, or
other in this analysis. The STS method for imputation was used for missing variables with categorical
variables assumed to have the lowest risk category and continuous variables imputed to the mean.15
Variables with less than 5% missingness were candidate variables, with the exception of right atrial
pressure, which had 32.7% missingness.15 Backward selection using a P value cutoff threshold of
<.001 was used to select variables in the final multivariable model. The model selection process
excluded the variable of interest—center status—to enable inference about the association of center
status after model selection,16 with a priori inclusion in the final model. A sensitivity analysis was
performed to determine whether transplant center volume was associated with listing strategies
with centers categorized into volume categories based on the number of transplants performed in
the year of LVAD implant (0 transplants, 1-9 transplants, 10-19 transplants, 20-29 transplants, 30-39
transplants, 40-49 transplants, 50-59 transplants, and >60 transplants).
Time-to-event analyses accounting for competing events were used to assess the association
between center status and receipt of transplant within 2 years following LVAD implant. First, the
cumulative incidences for transplant and death by center status were determined. Next, a
multivariate cause-specific Cox proportional hazards regression model was performed with variable
selection for the primary outcome of transplant in the 2 years following LVAD with death as a
competing event and censoring at last follow-up. With the association of transplant center status and
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listing strategy known, this analysis was performed with variable selection without device strategy
included. A robustness analysis was performed to examine the interaction between transplant center
status and device strategy. Sensitivity analyses included (1) adjusting for device strategy (eg, BTT or
destination therapy), (2) limiting the sample to recipients younger than 70 years, (3) using a P value
cutoff of <.10 to select variables in the final multivariable model, (4) not including right atrial pressure
as a candidate variable, (5) testing whether the association between center status and transplant
varied by device strategy, and (6) reestimating the model using a propensity score–matching
method. The propensity for receiving care at an LVAD/transplant center was estimated using
variables associated with listing strategies and transplant eligibility (eg, device strategy, patient
demographic characteristics, comorbidities, region, and year) (eTable 2 in Supplement 1). Patients
were matched 1:1 using the greedy matching method.17 A 2-tailed P ⱕ .05 was considered statistically
significant.

Results
In total, 22 221 patients with a median age of 59.0 (IQR, 50.0-67.0) years, of whom 17 420 (78.4%)
were men and 4801 were women (21.6%), underwent primary durable continuous-flow LVAD
implant from April 1, 2012, to June 30, 2020 (Table 1; eFigure in Supplement 1). Table 1 displays the
baseline characteristics of recipients by center status, with 14.2% (n = 3156) receiving a durable LVAD
at an LVAD-only center. Recipients at an LVAD-only center were older and more likely to be admitted
for LVAD placement. LVAD-only centers had fewer beds, were more likely to be in cities outside of
the largest 100 cities in the US, and were less likely to be affiliated with a medical school or have
graduate medical education than LVAD/transplant centers (eTable 3 in Supplement 1). The number
of LVAD-only centers (P < .001 for trend) and LVAD procedures performed (P = .003 for trend) at
LVAD-only centers increased during the study period (Figure 1). There was a smaller increase in the
number of LVAD/transplant centers (P = .001 for trend), without an increase in LVAD implants at
such centers from 2013 to 2019 (P = .91 for trend).
A BTT strategy was used for 37.7% (n = 7186) of patients who received implants at LVAD/
transplant centers and 16.9% (n = 532) of those who received implants at LVAD-only centers. Results
of the multivariable logistic regression exploring the association between transplant center status
and BTT listing are displayed in Table 2. Compared with LVAD-only centers, there was a 1.79 (95% CI,
1.35-2.38; P < .001) increased odds of a patient being considered for transplant (implant as BTT
LVAD) at LVAD/transplant centers. Patients presenting to an LVAD-only center were a mean of 6.21%
(95% CI, 3.27%-9.15%) less likely to receive an LVAD with a BTT intent (posterior estimation, 0.31;
95% CI, 0.28-0.33) than patients at an LVAD/transplant center (posterior estimation, 0.37; 95% CI,
0.35-0.39) after adjusting for patient clinical and center characteristics. In the sensitivity analysis
evaluating a transplant volume association (eTable 4 in Supplement 1), there was a significant
increase in the odds of BTT listing at LVAD/transplant centers that performed fewer than 10
transplants annually compared with LVAD-only centers (odds ratio, 1.48; 95% CI, 1.05-2.08). There
was a significant trend in increased odds of BTT listing among centers with increasing transplant
volume (P value trend test <.001). Among centers performing more than 60 transplants in the year
of LVAD implant, there was a 2.77 (95% CI, 1.87-4.09) increased odds of implanting an LVAD in a
patient for a BTT strategy vs LVAD-only centers.
The 2-year transplant rate following LVAD implant was 25.6% at LVAD/transplant centers and
11.9% at LVAD-only centers; death occurred in 23.9% of patients at LVAD/transplant centers and
26.4% at LVAD-only centers (Figure 218). The multivariable cause-specific Cox proportional hazard
model results are shown in Table 3. In LVAD/transplant centers, LVAD recipients had an associated
33% increased rate of transplant compared with LVAD-only centers at any given time during 2 years
(adjusted hazard ratio [HR], 1.33; 95% CI, 1.17-1.51). Rates of death while receiving LVAD support were
equivalent at 2 years between center types in the multivariable model (adjusted HR, 0.99; 95% CI,
0.90-1.08) (eTable 5 in Supplement 1).
JAMA Network Open. 2022;5(11):e2240646. doi:10.1001/jamanetworkopen.2022.40646 (Reprinted)
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Table 1. Baseline Characteristics of LVAD Recipients
No. (%)
Characteristic

Overall
(N = 22 221)

LVAD only
(n = 3156)

LVAD/transplant
(n = 19 065)

P valuea

59.0 (50.0-67.0)

63.5 (54.0-71.0)

59.0 (49.0-66.0)

<.001

Demographic characteristics
Age, median (IQR), y
Sex
Male

17 420 (78.4)

2472 (78.3)

14 948 (78.4)

Female

4801 (21.6)

684 (21.7)

4117 (21.6)

.94

Blood type
O

10 699 (48.1)

1474 (46.7)

9225 (48.4)

A

7925 (35.7)

1166 (36.9)

6759 (35.5)

B

2842 (12.8)

411 (13.0)

2431 (12.8)

AB

755 (3.4)

105 (3.3)

650 (3.4)

Black

5857 (26.4)

791 (25.1)

5066 (26.6)

White

14 385 (64.7)

2096 (66.4)

12 289 (64.5)

Other

1979 (8.9)

269 (8.5)

1710 (9.0)

Hispanic ethnicity

1492 (6.7)

188 (6.0)

1304 (6.8)

.07

BMI, median (IQR)

27.9 (24.1-32.5)

27.7 (23.9-32.5)

27.9 (24.1-32.5)

.89

None/unknown

5995 (27.0)

858 (27.2)

5137 (26.9)

Greater than high school

8727 (39.3)

1281 (40.6)

7446 (39.1)

High school

7499 (33.7)

1017 (32.2)

6482 (34.0)

Single

4501 (20.3)

545 (17.3)

3956 (20.8)

Married

13 390 (60.3)

1937 (61.4)

11 453 (60.1)

Divorced/separated or other

4330 (19.5)

674 (21.4)

3656 (19.2)

Medicare

4686 (21.1)

983 (31.1)

3703 (19.4)

Medicaid

1398 (6.3)

202 (6.4)

1196 (6.3)

Commercial and HMO

3138 (14.1)

472 (15.0)

2666 (14.0)

Other

12 999 (58.5)

1499 (47.5)

11 500 (60.3)

Axial

10 898 (49.0)

1832 (58.0)

9066 (47.6)

Hybrid magnetically levitated

6485 (29.2)

432 (13.7)

6053 (31.7)

Fully magnetically levitated

4838 (21.8)

892 (28.3)

3946 (20.7)

1

3562 (16.0)

366 (11.6)

3196 (16.8)

2

7716 (34.7)

1072 (34.0)

6644 (34.8)

3

7804 (35.1)

1249 (39.6)

6555 (34.4)

4-7

3139 (14.1)

469 (14.9)

2670 (14.0)

I

22 (0.1)

2 (0.1)

20 (0.1)

II

189 (0.9)

31 (1.0)

158 (0.8)

III

3324 (15.0)

393 (12.5)

2931 (15.4)

IV

18 686 (84.1)

2730 (86.5)

15 956 (83.7)

Congenital heart disease

114 (0.5)

6 (0.2)

108 (0.6)

Ischemic

9749 (43.9)

1520 (48.2)

8229 (43.2)

NICM

11 717 (52.7)

1550 (49.1)

10 167 (53.3)

Restrictive CM

444 (2.0)

54 (1.7)

390 (2.0)

Unknown

197 (0.9)

26 (0.8)

171 (0.9)

.32

Raceb

.10

Educational level

.12

Marital status

<.001

Payer

<.001

Clinical characteristics
Device type

<.001

STS Intermacs Patient Profile

<.001

NYHA functional class

<.001

Etiology of heart failure

<.001

(continued)
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Table 1. Baseline Characteristics of LVAD Recipients (continued)
No. (%)
Overall
(N = 22 221)

Characteristic

LVAD only
(n = 3156)

LVAD/transplant
(n = 19 065)

P valuea

Admitting diagnosis or planned
implant
Heart failure

14 645 (65.9)

1727 (54.7)

12 918 (67.8)

Cardiac surgery

261 (1.2)

65 (2.1)

196 (1.0)

Noncardiac medical problem

160 (0.7)

36 (1.1)

124 (0.7)

LVAD placement

5861 (26.4)

1124 (35.6)

4737 (24.8)

Total artificial heart placement

3 (0.0)

0

3 (0.0)

Other cardiology

661 (3.0)

101 (3.2)

560 (2.9)

<.001

Acute MI

571 (2.6)

98 (3.1)

473 (2.5)

Noncardiac surgery

11 (0.0)

3 (0.1)

8 (0.0)

Unknown

48 (0.2)

2 (0.1)

46 (0.2)

ICD

17 508 (78.8)

2542 (80.5)

14 966 (78.5)

.01

Any transplant-limiting
comorbidity

13 456 (60.6)

2435 (77.2)

11 021 (57.8)

<.001

Chronic kidney disease

1584 (7.1)

293 (9.3)

1291 (6.8)

<.001

Current tobacco use

1146 (5.2)

220 (7.0)

926 (4.9)

<.001

Frailty

1098 (4.9)

261 (8.3)

837 (4.4)

<.001

History of tobacco use

1748 (7.9)

325 (10.3)

1423 (7.5)

<.001

Obesity

2675 (12.0)

466 (14.8)

2209 (11.6)

<.001

Limited social support

873 (3.9)

123 (3.9)

750 (3.9)

.96

2012

1639 (7.4)

177 (5.6)

1462 (7.7)

2013

2557 (11.5)

281 (8.9)

2276 (11.9)

2014

2678 (12.1)

297 (9.4)

2381 (12.5)

2015

2993 (13.5)

382 (12.1)

2611 (13.7)

2016

2688 (12.1)

321 (10.2)

2367 (12.4)

2017

2461 (11.1)

402 (12.7)

2059 (10.8)

2018

2864 (12.9)

500 (15.8)

2364 (12.4)

2019

3083 (13.9)

570 (18.1)

2513 (13.2)

2020

1258 (5.7)

226 (7.2)

1032 (5.4)

Comorbidities

Implant year

<.001

Abbreviations: BMI, body mass index (calculated as
weight in kilograms divided by height in meters
squared); CM, cardiomyopathy; HMO, health
maintenance organization; ICD, implantable
cardioverter-defibrillator; LVAD, left ventricular assist
device; MI, myocardial infarction; NICM, nonischemic
cardiomyopathy; NYHA, New York Heart Association;
STS, Society of Thoracic Surgeons.
a

P values determined using 2-sided Mann-Whitney
test for continuous variables and χ2 tests for
categorical variables.

b

Race was reported by sites and categorized as
American Indian or Alaska Native, Asian, African
American or Black, Hawaiian or other Pacific Islander,
White, Unknown/Undisclosed, or Other/none of the
above. Due to low numbers in groups, race was
categorized as White, Black, or other in this analysis.

Figure 1. Number of Centers and Left Ventricular Assist Devices (LVADs) Performed by Center Type by Year
A No. of centers by year

B

120

Yearly LVAD implantations by center type
3000

LVAD/transplant

LVAD/transplant
2500

2000

No. of LVADs

No. of centers

100

80

60

1500

1000

LVAD only

LVAD only

40

500

20

0
2012

2013

2014

2015

2016

2017

2018

2019

2020

2013

Year

A, The number of centers implanting LVADs increased for both LVAD-only (P < .001 for
trend) and LVAD/transplant centers (P = .001 for trend) from 2012 to 2020. B, The
number of LVADs implanted at LVAD-only centers increased in the study period

2015

2016

2017

2018

2019

Year

(P = .003 for trend), but there was no significant change in volume (P = .91 for trend) at
LVAD/transplant centers from 2013 to 2019, the years in which 365 days of data
available.
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Table 2. Association of Transplant Center Status With Bridge-to-Transplant Listing Strategy
Variable

OR (95% CI)

P value

Type of center
LVAD only

1 [Reference]

NA

LVAD/transplant

1.79 (1.35-2.38)

<.001

Axial

1 [Reference]

NA

Hybrid magnetically levitated

8.21 (7.23-9.31)

<.001

Fully magnetically levitated

13.60 (11.20-16.51)

<.001

Device type

Age (per year)

0.96 (0.95-0.96)

<.001

BMI

0.98 (0.98-0.99)

<.001

Albumin (per 1 g/dL)

1.25 (1.17-1.35)

<.001

Total bilirubin (per mg/dL)

0.93 (0.90-0.95)

<.001

Right atrial pressure (per 1 mm Hg)

0.99 (0.99-1.00)

.01

Black

0.84 (0.76-0.94)

.002

White

1 [Reference]

NA

Other

0.78 (0.67-0.91)

.002

No

1 [Reference]

NA

Yes

1.35 (1.22-1.50)

<.001

IV

1 [Reference]

NA

I-III

1.25 (1.11-1.40)

<.001

Racea

Presence of ICD

NYHA functional class

Educational level
Less than high school

1 [Reference]

NA

High school

1.12 (1.00-1.27)

.06

Above high school

1.39 (1.23-1.56)

<.001

Marital status
Single

1 [Reference]

NA

Married

1.61 (1.43-1.80)

<.001

Divorced/separated or other

1.44 (1.26-1.65)

<.001

Payer
Medicare

1 [Reference]

NA

Medicaid

0.95 (0.78-1.16)

.61

Commercial and HMO

1.29 (1.11-1.49)

<.001

Other

1.31 (1.11-1.54)

.002

Primary diagnosis
Ischemic CM

1 [Reference]

NA

Congenital heart disease

1.04 (0.60-1.82)

.88

NICM

1.24 (1.12-1.37)

<.001

Restrictive CM

0.87 (0.64-1.17)

.34

Unknown

0.65 (0.42-0.99)

.05

2012

1 [Reference]

NA

2013

0.59 (0.49-0.70)

<.001

2014

0.51 (0.42-0.61)

<.001

2015

0.43 (0.40-0.52)

<.001

2016

0.36 (0.30-0.44)

<.001

2017

0.24 (0.19-0.30)

<.001

2018

0.08 (0.06-0.10)

<.001

2019

0.03 (0.02-0.03)

<.001

2020

0.02 (0.02-0.03)

<.001

Implant year

(continued)
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Table 2. Association of Transplant Center Status With Bridge-to-Transplant Listing Strategy (continued)
Variable

OR (95% CI)

P value

1

1 [Reference]

NA

2

0.49 (0.25-0.98)

.04

3

0.30 (0.15-0.62)

.001

4

0.41 (0.18-0.90)

.03

5

0.60 (0.30-1.20)

.14

6

0.81 (0.31-2.14)

.67

7

0.50 (0.24-1.05)

.07

8

0.79 (0.33-1.88)

.59

9

0.82 (0.38-1.76)

.60

10

0.46 (0.21-0.97)

.04

11

0.46 (0.22-0.94)

.03

≥500

1 [Reference]

NA

50-99

0.94 (0.22-4.05)

.93

100-199

0.96 (0.17-5.43)

.96

200-299

1.53 (0.77-3.03)

.22

300-399

1.86 (1.05-3.30)

.03

400-499

0.90 (0.58-1.37)

.61

Yes

1 [Reference]

NA

No

0.43 (0.24-0.78)

.006

State run

1 [Reference]

NA

Hospital district

0.86 (0.41-1.79)

.68

Not-for-profit church

0.87 (0.46-1.66)

.68

UNOS region

No. of hospital beds

ACGME programs

Hospital authority

Other not for profit

0.79 (0.50-1.26)

.33

For-profit partnership

1.01 (0.25-4.04)

.99

For-profit corporation

0.65 (0.26-1.62)

.35

Transplant-limiting comorbidity
None

1 [Reference]

NA

Any

0.05 (0.05-0.05)

<.001

0.79 (0.70-0.90)

<.001

Prior CABG

Abbreviations: ACGME, Accreditation Council for
Graduate Medical Education; BMI, body mass index;
CABG, coronary artery bypass graft surgery; CM,
cardiomyopathy; HMO, health maintenance
organization; ICD, implantable
cardioverter-defibrillator; LVAD, left ventricular assist
device; NA, not applicable; NICM, nonischemic
cardiomyopathy; NYHA, New York Heart Association;
OR, odds ratio; UNOS, United Network for
Organ Sharing.
a

Race was reported by sites and categorized as
American Indian or Alaska Native, Asian, African
American or Black, Hawaiian or other Pacific Islander,
White, Unknown/Undisclosed, or Other/none of the
above. Due to low numbers in groups, race was
categorized as White, Black, or other in this analysis.

Robustness and Sensitivity Analyses
There was a significant interaction between center type and device strategy (eTable 6 in
Supplement 1). Compared with patients at LVAD-only centers, patients receiving implants at LVAD/
transplant centers had associated increased transplant rates of 25% for BTT (HR, 1.25; 95% CI, 1.051.47) and 63% (HR, 1.63; 95% CI, 1.31-2.04) for destination therapy; bridge to candidacy had
equivalent rates (HR, 1.05; 95% CI, 0.79-1.40). The inclusion of device strategy in the model (eTable 7
in Supplement 1) and limiting the sample to 19 143 recipients younger than 70 years (eTable 8 in
Supplement 1) did not appreciably change the findings between center status and outcomes. Among
patients younger than 70 years, those receiving an LVAD at an LVAD/transplant center had a 29%
higher transplant rate (HR, 1.29; 95% CI, 1.11-1.46). Not including right atrial pressure as a candidate
variable (eTable 9 in Supplement 1) and using a cutoff of P < .10 to select variables in the multivariable
model were not associated with changes in the results (eTable 10 and eTable 11 in Supplement 1).
Results of the propensity score–matched analysis were similar. Among the 1:1 matched 6266 LVAD
recipients, transplant occurred in 16.2% (n = 509) of patients at LVAD/transplant centers and 10.0%
(n = 310) of patients at LVAD-only centers; death occurred in 22.7% (n = 713) of patients at LVAD/
transplant centers and 22.6% (n = 709) of patients at LVAD-only centers. In adjusted models, there
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was an associated 35% increased rate (HR, 1.35; 95% CI, 1.16-1.59) of transplant at LVAD/transplant
centers (eTable 12 in Supplement 1).

Discussion
This contemporary national analysis of durable LVAD implant documents systemic inequities in
transplant access for patients receiving a durable LVAD at LVAD-only centers. Receiving a durable
LVAD at a center that also performs heart transplants was associated with a higher odds of patients
being considered a transplant candidate at the time of LVAD implant and with increased rates of
heart transplant in the 2 years following LVAD implant. There was no significant difference in
postimplant LVAD mortality between LVAD/transplant and LVAD-only centers within 2 years of
follow-up.
A 2018 study reported similar 1-year outcomes for death and major adverse events for patients
receiving durable LVAD therapy at transplant or nontransplant LVAD centers.19 The present study
builds on these findings by noting no significant differences in LVAD survival up to 2 years following
LVAD implant in this contemporary cohort.
To our knowledge, the finding of an associated increase in heart transplant after LVAD at centers
that perform transplants is novel. Nontransplant LVAD centers are increasing in number. The CMS
national coverage determination has made establishing an LVAD-only program less restrictive now
that there is no longer the need to form a relationship with a Medicare-approved heart transplant
center.9 The decreased barriers to establishing a durable LVAD program at a non–Medicare-approved
heart transplant center will likely lead to continued increases in the number of nontransplant centers
and LVAD volumes at these centers—trends that were already occurring before the change. Although
there should be enthusiasm for the potential of LVAD-only centers to increase access to LVAD, it
appears that receiving an LVAD at a center that does not perform transplants results in differential
assessment of transplant eligibility at the time of LVAD implant and inequities in receipt of transplant.
This adverse association between transplant eligibility and access for patients receiving an LVAD at
an LVAD-only center occurred before the CMS policy change that removed the requirement for
shared care for LVAD candidates being considered for transplant at a Medicare-approved transplant
center. This finding is important because the lower levels of transplant eligibility and access may
worsen under the new, less restrictive CMS policy and heart transplant remains the best long-term

Figure 2. Cumulative Incidence of Transplant and Death in the 2 Years Following Left Ventricular Assist Device (LVAD) Implant by Center Status
A Transplant

B

Death
0.4

Cumulative incidence of death

Cumulative incidence of transplant

0.4

0.3
LVAD/transplant
0.2

0.1
LVAD only
0

0.3
LVAD only
0.2
LVAD/transplant

0.1

0
0

3
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A, The rate of heart transplant in the 2 years following LVAD implant was 25.6% at LVAD/
transplant centers and 11.9% at LVAD-only centers (P < .001). B, There was no significant
difference in the rate of death at LVAD/transplant centers (23.9%) and LVAD-only

6

9

12

15

18

21

24

Months since LVAD

centers (26.4%) (P = .66). The number at risk is not reported given the presence of a
competing risk.18
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Table 3. Results of Multivariable Cause-Specific Cox Proportional Hazards Regression Model for Transplant
in the 2 Years Following LVAD
Variable

HR (95% CI)

P value

Type of center
LVAD only

1 [Reference]

NA

LVAD/transplant

1.33 (1.17-1.51)

<.001

Device type
Axial

1 [Reference]

NA

Hybrid magnetically levitated

1.57 (1.46-1.70)

<.001

Fully magnetically levitated

1.20 (1.04-1.38)

.01

0.99 (0.99-0.99)

<.001

Age (per year)
Blood type
O

1 [Reference]

NA

A

1.63 (1.53-1.74)

<.001

B

1.67 (1.52-1.82)

.65

AB

2.31 (1.99-2.67)

<.001

BMI

0.98 (0.97-0.98)

<.001

Right atrial pressure, per 1 mm Hg

1.01 (1.00-1.01)

.001

Black

0.73 (0.68-0.79)

<.001

White

1 [Reference]

NA

Other

0.85 (0.77-0.94)

.002

Racea

Presence of ICD
No

1 [Reference]

NA

Yes

1.20 (1.12-1.30)

<.001

1.27 (1.12-1.43)

<.001

Single

1 [Reference]

NA

Married

1.21 (1.11-1.32)

.32

Divorced/separated or other

1.16 (1.05-1.28)

.004

Ventilator use during hospitalization
Marital status

Payer
Medicare

1 [Reference]

NA

Medicaid

0.97 (0.82-1.16)

.74

Commercial and HMO

1.62 (1.44-1.82)

<.001

Other

1.29 (1.14-1.46)

<.001

Primary diagnosis
Ischemic CM

1 [Reference]

NA

Congenital heart disease

0.75 (0.50-1.12)

.16

NICM

1.13 (1.05-1.22)

.001

Restrictive CM

0.84 (0.67-1.06)

.14

Unknown

0.77 (0.54-1.08)

.13

Implant year
2012

1 [Reference]

NA

2013

0.78 (0.68-0.89)

<.001

2014

0.75 (0.66-0.85)

<.001

2015

0.83 (0.73-0.94)

.004

2016

0.89 (0.78-1.02)

.09

2017

0.77 (0.66-0.91)

.002

2018

0.66 (0.56-0.79)

<.001

2019

0.47 (0.38-0.58)

<.001

2020

0.38 (0.25-0.57)

<.001
(continued)
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Table 3. Results of Multivariable Cause-Specific Cox Proportional Hazards Regression Model for Transplant
in the 2 Years Following LVAD (continued)
Variable

HR (95% CI)

P value

UNOS region
1

1 [Reference]

NA

2

0.64 (0.54-0.75)

<.001

3

0.54 (0.46-0.65)

<.001

4

0.52 (0.44-0.62)

<.001

5

0.82 (0.70-0.95)

<.001

6

0.93 (0.76-1.14)

<.001

7

0.66 (0.56-0.77)

.008

8

0.78 (0.64-0.95)

.49

9

0.69 (0.58-0.83)

<.001

10

0.64 (0.55-0.75)

.01

11

0.64 (0.55-0.76)

<.001

No. of hospital beds
≥500

1 [Reference]

NA

50-99

2.59 (1.14-5.88)

.02

100-199

1.94 (0.86-4.38)

.11

200-299

0.93 (0.80-1.09)

.37

300-399

1.66 (1.39-1.98)

<.001

400-499

1.45 (1.32-1.58)

<.001

US city rank size
1-25

1 [Reference]

NA

26-50

0.74 (0.66-0.82)

<.001

51-75

0.89 (0.78-1.00)

.06

76-100

1.00 (0.87-1.16)

.95

Greater than top 100

0.63 (0.58-0.69)

<.001

Medical school affiliation
Yes

1 [Reference]

NA

No

0.26 (0.18-0.38)

<.001

State run

1 [Reference]

NA

Hospital district

1.04 (0.89-1.22)

.61

Hospital authority

Not-for-profit church

0.56 (0.48-0.66)

<.001

Other not for profit

0.82 (0.75-0.91)

<.001

For-profit partnership

1.01 (0.70-1.46)

.95

For-profit corporation

0.52 (0.38-0.71)

<.001

Transplant-limiting comorbidity
None

1 [Reference]

NA

Any

0.36 (0.34-0.39)

<.001

0.83 (0.75-0.92)

<.001

Prior CABG

Abbreviations: BMI, body mass index; CABG, coronary
artery bypass graft surgery; CM, cardiomyopathy;
HMO, health maintenance organization; HR, hazard
ratio; ICD, implantable cardioverter-defibrillator; LVAD,
left ventricular assist device; NA, not applicable; NICM,
nonischemic cardiomyopathy; UNOS, United Network
for Organ Sharing.
a

Race was reported by sites and categorized as
American Indian or Alaska Native, Asian, African
American or Black, Hawaiian or other Pacific Islander,
White, Unknown/Undisclosed, or Other/none of the
above. Due to low numbers in groups, race was
categorized as White, Black, or other in this analysis.

treatment strategy for most eligible patients with advanced HF because long-term survival outcomes
are dramatically different.10,20,21
In addition, the finding of the interaction of therapeutic intent and receipt of an LVAD merits
discussion. Recent work from the Multicenter Study of MagLev Technology in Patients Undergoing
Mechanical Circulatory Support Therapy With HeartMate 3 trial has documented that LVADs
effectively improve quality of life and survival regardless of therapeutic intent.22 With this result, and
recognizing the challenges in identifying LVAD intent and dynamic changes in patient status,23,24
CMS removed the therapeutic intent designation.9 In the present study, there was an association
between having a transplant program and differential determination of transplant candidacy and
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increased access to transplant after LVAD implant, not only for patients initially considered transplant
candidates (BTT) but also for destination therapy intent patients at LVAD/transplant centers. This
finding could occur because of disparities in either reevaluation for transplant or improvements in
transplant candidacy after LVAD for patients at LVAD/transplant centers (eg, improved kidney
function following LVAD implant).25 Determining transplant eligibility is complex,26 particularly given
the dynamic course of HF.23,24 A patient with advanced HF may be ineligible because of
comorbidities, substance use, psychological concerns, or inadequate social support.26,27 LVAD/
transplant centers appear to be more aggressively pursuing transplants even for patients initially
considered ineligible.
These collective results may raise questions for CMS policy makers, particularly when
considering the modifications to the adult heart allocation system.28 The US adult heart allocation
system was modified by the Organ Procurement and Transplantation Network in October 2018 as
part of a strategic goal to provide equity in access to transplant by prioritizing those at the highest risk
for death on the waiting list. The revisions to the Organ Procurement and Transplantation Network/
United Network for Organ Sharing adult heart allocation system have resulted in widespread changes
in treatment strategies for patients being considered for transplant, with significantly decreased use
of durable LVADs as a bridging strategy and a corresponding increased use of short-term mechanical
circulatory support devices to bridge patients to transplant, which itself appears to have reduced
equity in transplant.28-30 The changes have significantly reduced the likelihood of transplant after
durable LVAD implant unless candidates are listed at higher urgency status due to an LVAD
complication or clinical deterioration.30 The reality is that durable LVADs are much less likely to be a
bridge to the best therapy (ie, transplant) in the current allocation system. As a result, there is a
critical need to select appropriate durable LVAD and transplant candidates at the initial evaluation. As
currently designed and implemented, the CMS policy will likely further challenge equity in access to
transplant for patients seeking care at nontransplant centers and may have the unintended
consequence of contributing to increasing inequities in access to transplants, as has been feared.24
There is a potential role of registries to monitor equity in access to advanced therapies, although
there is not currently a registry that includes candidates for both LVAD and transplant. Rather, only
patients who receive an LVAD (STS Intermacs) or are listed for transplant (United Network for Organ
Sharing) are included in a registry. Although we agree with the views expressed in the recent letter
endorsed by the STS, the American College of Cardiology, the Heart Failure Society of America, and
the American Association for Thoracic Surgery about the opportunity to use registry data to compare
practices between institutions to ensure appropriate consideration before LVAD,31 our work suggests
there is a need to ensure most patients without an obvious contraindication to transplant (eg, active
tobacco use) are evaluated at transplant centers before durable LVAD and following LVAD implant to
assess ongoing transplant eligibility. In addition to monitoring access to transplants, determining
whether the increased access will impact documented inequities in access to LVAD among
underserved groups, including women and Black patients with HF, will remain critical.32-35

Limitations
This study has several limitations. The study used observational registry data, which likely have
unobserved heterogeneity, unmeasured confounding, and possible underreporting of outcomes
data despite routine hospital audits by STS Intermacs and the low level of overall missingness for
candidate variables. Nonetheless, STS Intermacs remains the most comprehensive registry of
durable mechanical circulatory support devices with detailed patient-level variables in the US and is
well positioned to support evaluations of variation in practice and outcomes. Furthermore, similar
results using multiple rigorous sensitivity analyses, including propensity score–matching methods,
support the robustness of the study findings. Patients undergoing transplants were censored during
LVAD survival analyses, and information on urgent transplant listing for device complications was
not available. In addition, this analysis focused on outcomes at 2 years. Thus, this study cannot
examine whether longer-term outcomes may be different between center types.
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Conclusions
The findings of this study suggest systemically different approaches to consideration for transplant
candidacy at LVAD centers that perform transplants compared with LVAD-only centers. Furthermore,
LVAD recipients at nontransplant centers may have reduced access to transplants. Recent CMS policy
changes will likely have the unintended consequence of increasing disparities in access to transplants
despite increasing LVAD access.
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